FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs
Executive Summary
FDA's oversight of clinical trials is becoming an increasingly significant factor in regulatory delays for some products, and a recent warning letter could have a very broad impact: it cites a clinical investigator for six trials related to three separate NDAs